Clinical Trials Logo

SIRS clinical trials

View clinical trials related to SIRS.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05703802 Recruiting - Sepsis Clinical Trials

Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.

Start date: July 1, 2022
Phase:
Study type: Observational [Patient Registry]

Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids. Within our workgroup we found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice. However, it is unknown if this applies also in humans. By using an ELISA-assay we want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data.

NCT ID: NCT05023954 Recruiting - Sepsis Clinical Trials

mSEP: Testing of Physiological and Immune-metabolic Blood Markers for Maternal Sepsis

Start date: October 12, 2020
Phase:
Study type: Observational

A prospective observational cohort study investigating physiological parameters vs biological markers of whole blood in septic and non-septic pregnant woman to predict systemic immune health

NCT ID: NCT04289506 Recruiting - Sepsis Clinical Trials

Validation of Molecular and Protein Biomarkers in Sepsis

VAMp-sepsis
Start date: February 25, 2020
Phase:
Study type: Observational

Background: Sepsis (blood poisoning) is a clinical syndrome characterised by a dysregulated host response to infection causing life-threatening organ dysfunction which results in admission to an intensive care unit. It typically shows an initial harmful inflammation resulting from the immune system's overreaction to a severe infection. It is a major healthcare problem, affecting millions of people worldwide. In the UK, it kills over 37,000 people/year, costing the NHS £2.5 billion a year, and is increasing in incidence. Despite extensive efforts to tackle this burden, at present, however, there are no specific and effective therapies for this illness. Sepsis is a potentially life-threatening condition caused by a severe infection. When someone develops sepsis, inflammation occurs not just at the site of the infection but throughout the whole body. This widespread inflammation can be very harmful. It is known that similar responses occur in other conditions, not relating to infection. The investigators are recruiting patients with severe infections causing organ failure (also known as severe sepsis/ septicaemia and septic shock) and also patients where widespread inflammation, not related to infection, causes organ failure. In this study the investigators hope to find out whether certain groups of genetic and blood based protein markers of sepsis can forewarn the clinicians to this condition and also highlight patients who are responding well to the treatment. Although it is known that the majority of the patients suffering from sepsis will survive their ICU stay and leave the hospital alive, there is insufficient data how these patients do on a longer term, i.e. after some time at home. To date there is little information on the ability of the observed genetic and blood based protein markers to predict the functional status of the patients surviving these conditions.

NCT ID: NCT03884595 Recruiting - Sepsis Clinical Trials

Early Identification of Sepsis in Children

Start date: December 1, 2019
Phase:
Study type: Observational

This observational nation-wide study is focused on evaluation of the new possible biomarkers for pediatric sepsis and their specificity/sensitivity in combination with usual diagnostic markers for sepsis in the terms of early identification of sepsis, severe sepsis, and septic shock.

NCT ID: NCT02922998 Recruiting - Sepsis Clinical Trials

CD64 and Antibiotics in Human Sepsis

CD64SEPLDX
Start date: September 2016
Phase: N/A
Study type: Observational

The purpose of the study is to find out whether CD64 expression on neutrophils measured by a new bedside test (LeukoDx) within 30 minutes is associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis.

NCT ID: NCT01493492 Recruiting - Sepsis Clinical Trials

Urinary Proteomics Analysis for Sepsis and Prognosis

Start date: May 2010
Phase: N/A
Study type: Observational

As a noninvasive examination, urinary proteomics is a very useful tool to identify renal disease. The purpose of the present study was to find differential proteins among patient with SIRS and sepsis(included survivors and non-survivors), and to screen potential biomarkers for the early diagnosis of sepsis and its prognosis. Urinary proteins were identified by iTRAQ labeling and LC-MS/MS. The bioinformatics analysis was performed with the Mascot software and the International Protein Index (IPI) and the Gene Ontology (GO) Database and KEGG pathway Database. The differentially expressed proteins were verified by Western blot by another sample collected from clinical.

NCT ID: NCT01493466 Recruiting - Sepsis Clinical Trials

Serum Proteomics Analysis for Sepsis

Start date: May 2010
Phase: N/A
Study type: Observational

Serum proteomics is a very useful tool to identify various disease. The purpose of the present study was to find differential proteins among patient with normal, SIRS, sepsis, severe sepsis, death and to screen potential biomarkers for their dynamic changes. Serum proteins were identified by iTRAQ labeling and LC-MS/MS. The bioinformatics analysis was performed with the Mascot software and the International Protein Index (IPI) and the Gene Ontology (GO) Database and KEGG pathway Database. The differentially expressed proteins were verified by Western blot by another sample collected from clinical.

NCT ID: NCT01169168 Recruiting - Sepsis Clinical Trials

Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome (SIRS), Sepsis or Chronicle Liver Disease on Intensive Care Units (ICU)

Start date: April 2010
Phase: N/A
Study type: Observational

In this study patients with 1. chronicle liver diseases - primary biliary cirrhosis - primary sclerosing cholangitis - alcoholic liver cirrhosis - hepatitis b or C - Wilson's disease - cryptogenic cirrhosis 2. Septic Inflammatory Response Syndrome (SIRS) - sepsis - septic shock 3. patients after lysis should be included Blood samples will be gathered from the patients to measure fibrinogen with 5 different methods. The methods are: - Clauss fibrinogen - PT-Derived fibrinogen - immunoturbidimetric method - heat-precipitated fibrinogen - Schulz fibrinogen The result of these tests will be correlated with laboratory values which are gathered in routine and the clinical outcomes.

NCT ID: NCT01155674 Recruiting - Sepsis Clinical Trials

Innate Immune Functions of Immature Neutrophils

Start date: May 2010
Phase: N/A
Study type: Observational

Polymorphonuclear neutrophils, or granulocytes, are essential effector cells of the innate immune system against bacterial infections. Their role in sepsis has been long established as the primary phagocyte to clear the infectious process. In the early phase of sepsis, one observes a massive recruitment of immature neutrophils from the bone marrow into peripheral blood, the so-called "band forms" or "left shift cells". Despite the daily clinical use of neutrophil band forms count in the care of septic patients and their abundance in septic blood, no information exists on the fate of these cells, nor on their capacity to mount an efficient innate immune response. It is the goal of this proposal to study the fate and the innate immune functions of immature neutrophils obtained in patients with early septic shock. Immature neutrophils will be separated from mature neutrophils. The following functions will be studied ex vivo in mature vs. immature neutrophils from a series of patients with severe sepsis and septic shock: (1) surface expression of receptors of the innate immunity; (2) production of inflammatory mediators and reactive oxygen species in response to bacterial agonists; (3) chemotaxis; (4) phagocytosis of Gram-positive and Gram-negative bacteria; and (5) ex vivo viability (life span) and resistance to apoptosis. Importantly, the investigators have developed and mastered all in vitro assays and cell separation techniques necessary to address and answer these important questions. This project will undoubtedly shed light on the fate and function of a prominent leukocyte population circulating in patients with severe bacterial infections and sepsis.